Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Enhancement of mucociliary clearance (MCC) might be a potential target in treating COVID-19. The phytomedicine ELOM-080 is an MCC enhancer that is used to treat inflammatory respiratory diseases.
Patients/methods: This randomised, double-blind exploratory study (EudraCT number 2020-003779-17) evaluated 14 days' add-on therapy with ELOM-080 versus placebo in patients with COVID-19 hospitalised with acute respiratory insufficiency.
Results: The trial was terminated early after enrolment of 47 patients as a result of poor recruitment. Twelve patients discontinued prematurely, leaving 35 in the per-protocol set (PPS). Treatment with ELOM-080 had no significant effect on overall clinical status versus placebo (p = 0.49). However, compared with the placebo group, patients treated with ELOM-080 had less dyspnoea in the second week of hospitalisation (p = 0.0035), required less supplemental oxygen (p = 0.0229), and were more often without dyspnoea when climbing stairs at home (p < 0.0001).
Conclusion: These exploratory data suggest the potential for ELOM-080 to improve respiratory status during and after hospitalisation in patients with COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007397 | PMC |
| http://dx.doi.org/10.1007/s12325-022-02135-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of herbal medicine as an add-on to antipsychotics in patients with schizophrenia spectrum disorders accompanied by depression: A systematic review and meta-analysis.
Integr Med Res
March 2026
KM Science Research Division, Korea Institute of Oriental Medicine, South Korea.
Background: Depression is a common comorbidity of schizophrenia spectrum disorder (SSDs) that affects functional outcomes and quality of life. This systematic review and meta-analysis evaluated the effectiveness of herbal medicine as an adjunct therapy to antipsychotics in patients with SSDs and comorbid depression.
Methods: Eight databases were searched from inception to January 2025 for randomized controlled trials (RCTs) evaluating herbal medicine combined with antipsychotics vs antipsychotics alone in patients with SSDs and comorbid depression.
Extracorporeal Photopheresis in Lung Transplantation: Present Applications and Emerging Research.
Transplant Direct
September 2025
Vienna Lung Transplant Program, Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy currently used as an add-on treatment for the prevention and management of organ rejection in lung transplantation. Thanks to its immunomodulatory properties and its ability to reduce the need for immunosuppressive therapies, ECP presents a promising therapeutic option, especially for high-risk patients with comorbidities, infections, or malignancies. This review provides a comprehensive overview of the current indications, clinical experience, and ongoing research surrounding the use of ECP in lung transplantation.
View Article and Find Full Text PDFApremilast treatment of immune-mediated inflammatory skin diseases: a narrative review.
Front Pharmacol
August 2025
Department of Dermatology, Zhongshan Second People's Hospital, Zhongshan, Guangdong, China.
Novel therapeutic approaches on molecular pathways are being developed to treat inflammatory and autoimmune cutaneous dermatoses. Apremilast is an orally administered small-molecule phosphodiesterase 4 (PDE4) inhibitor that upregulates intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels to mediate a large array of proinflammatory cytokines as well as exerts its anti-inflammatory functions and therapeutic efficacy in skin diseases rather than an immunosuppressive mode of action. Early-phase clinical trials have demonstrated its favorable efficacy such that the United States Food and Drug Administration (USFDA) has approved its use for the treatment of psoriasis, psoriatic arthritis, and Behçet's syndrome.
View Article and Find Full Text PDFRelapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?
Mult Scler J Exp Transl Clin
September 2025
Department of Neurology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
Background: In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.
Objectives: To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.
Methods: In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks.
Potential Effects of Computer-Based Cognitive Training on Postural Stability and Locomotion in Parkinson's Disease Patients: A Randomized Controlled Trial.
Ann Rehabil Med
August 2025
Department of Physical Therapy for Neurology and Neurosurgery, Faculty of Physical Therapy, Cairo University, Giza, Egypt.
Objective: To examine the short-term and long-term effects of computer-based cognitive training on postural stability, locomotion, and cognitive performance in Parkinson's disease (PD) patients.
Methods: Sixty-eight PD participated in this randomized-controlled trial, were randomly allocated into two groups; control group (GA) received a designed physiotherapy program for 60 minutes, and an experimental group (GB) got 30 minutes physiotherapy program as GA, along with 30 minutes of computerized cognitive training. Treatment sessions were three times/week for eight weeks.